LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 97

Search options

  1. Article ; Online: Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems.

    Esposito, Susanna / Argentiero, Alberto / Gramegna, Andrea / Principi, Nicola

    Expert opinion on pharmacotherapy

    2021  Volume 22, Issue 9, Page(s) 1193–1202

    Abstract: Introduction: Despite the amount of new information, the most effective approach for the diagnosis and treatment of : Areas covered: Despite significant improvement in the diagnosis and in the definition of diseases potentially associated with this ... ...

    Abstract Introduction: Despite the amount of new information, the most effective approach for the diagnosis and treatment of
    Areas covered: Despite significant improvement in the diagnosis and in the definition of diseases potentially associated with this pathogen, not all the problems related to
    Expert opinion: Improvement in
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Child ; Drug Resistance, Bacterial ; Humans ; Macrolides/therapeutic use ; Mycoplasma pneumoniae ; Pneumonia, Mycoplasma/drug therapy ; Pneumonia, Mycoplasma/epidemiology
    Chemical Substances Anti-Bacterial Agents ; Macrolides
    Language English
    Publishing date 2021-02-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2021.1882420
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case.

    Morlacchi, Letizia Corinna / Zanini, Umberto / Gramegna, Andrea / Faverio, Paola / Blasi, Francesco / Luppi, Fabrizio

    ERJ open research

    2023  Volume 9, Issue 6

    Abstract: Although the mechanisms are not known, this is a case of progressive interstitial lung involvement, with a NSIP radiological pattern, evolving in pulmonary fibrosis in a patient with von Hippel-Lindau syndrome, without extrapulmonary fibrosis. ...

    Abstract Although the mechanisms are not known, this is a case of progressive interstitial lung involvement, with a NSIP radiological pattern, evolving in pulmonary fibrosis in a patient with von Hippel-Lindau syndrome, without extrapulmonary fibrosis.
    Language English
    Publishing date 2023-11-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2827830-6
    ISSN 2312-0541
    ISSN 2312-0541
    DOI 10.1183/23120541.00504-2023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Comments on "PD-1 Inhibitor for Disseminated

    Lombardi, Andrea / Gramegna, Andrea / Gruarin, Paola / Grifantini, Renata / Gori, Andrea / Blasi, Francesco / Bandera, Alessandra

    Open forum infectious diseases

    2023  Volume 10, Issue 3, Page(s) ofad083

    Language English
    Publishing date 2023-02-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofad083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?

    Azzarà, Cecilia / Lombardi, Andrea / Gramegna, Andrea / Ori, Margherita / Gori, Andrea / Blasi, Francesco / Bandera, Alessandra

    BMC infectious diseases

    2023  Volume 23, Issue 1, Page(s) 573

    Abstract: Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the "exhausted" immune system and increasing the number of T cells active ... ...

    Abstract Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the "exhausted" immune system and increasing the number of T cells active against pathogens losing tolerogenic signalling, which has been linked to an increased risk of infectious events. We present the case of a 67-year-old man with locally advanced lung adenocarcinoma treated with the anti-PD-L1 durvalumab. Three months after immunotherapy started, an apparent radiological progression was found with elements suggesting a parenchymal superinfection associated with weight loss, asthenia, and sputum emission. A bronchoalveolar lavage resulted positive for Mycobacterium chimaera, and treatment with amikacin iv (for eight weeks) and daily azithromycin, ethambutol, and rifampicin was started. Thirteen months after treatment started, the patient is alive with a stable lung condition. The case highlights the risk of non-tuberculous mycobacteria lung disease (NTM-LD) in patients receiving ICIs treatment. We hypothesise that durvalumab induced an exaggerated immune response toward the mycobacteria, leading to immunopathology and overt clinical manifestations. Clinicians should be aware of this possibility in patients receiving ICIs developing new signs/symptoms related to the respiratory tract, especially in countries with a high prevalence of NTM-LD.
    MeSH term(s) Male ; Humans ; Aged ; Nontuberculous Mycobacteria ; Immune Checkpoint Inhibitors/adverse effects ; Mycobacterium avium Complex ; Mycobacterium Infections, Nontuberculous/drug therapy ; Adenocarcinoma of Lung ; Pneumonia, Bacterial ; Lung Neoplasms/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-09-04
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2041550-3
    ISSN 1471-2334 ; 1471-2334
    ISSN (online) 1471-2334
    ISSN 1471-2334
    DOI 10.1186/s12879-023-08537-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis.

    Daccò, Valeria / Alicandro, Gianfranco / Trespidi, Laura / Gramegna, Andrea / Blasi, Francesco Arturo

    Archives of gynecology and obstetrics

    2023  Volume 308, Issue 5, Page(s) 1657–1659

    Abstract: Cystic fibrosis (CF) causes infertility and subfertility due to various factors, including altered cervical mucus, delayed puberty, and hormonal imbalances. With the introduction of the CFTR modulator therapy elexacaftor-tezacaftor-ivacaftor, we have ... ...

    Abstract Cystic fibrosis (CF) causes infertility and subfertility due to various factors, including altered cervical mucus, delayed puberty, and hormonal imbalances. With the introduction of the CFTR modulator therapy elexacaftor-tezacaftor-ivacaftor, we have observed an increase in unplanned pregnancies among women undergoing ETI treatment in our CF center, despite repeated recommendations for strict fertility monitoring. It appears that these pregnancies are more likely attributed to reduced attention to the possibility of conception rather than contraceptive failure. The perception of subfertility developed by women with CF over time, before the era of modulators, can influence their long-term habits and lead to the underuse of contraceptive methods. While further research is needed to fully understand the effects of ETI on fertility, healthcare providers should be attentive to the fertility concerns of women with CF, particularly those treated with modulators in adulthood.
    MeSH term(s) Female ; Humans ; Pregnancy ; Cystic Fibrosis/complications ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/genetics ; Infertility ; Mutation ; Pregnancy, Unplanned ; Chloride Channel Agonists/therapeutic use ; Pyrazoles/therapeutic use
    Chemical Substances elexacaftor (RRN67GMB0V) ; ivacaftor (1Y740ILL1Z) ; tezacaftor ; Chloride Channel Agonists ; Pyrazoles
    Language English
    Publishing date 2023-07-30
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 896455-5
    ISSN 1432-0711 ; 0932-0067
    ISSN (online) 1432-0711
    ISSN 0932-0067
    DOI 10.1007/s00404-023-07153-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um I Zs.55: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.

    Amati, Francesco / Stainer, Anna / Polelli, Veronica / Mantero, Marco / Gramegna, Andrea / Blasi, Francesco / Aliberti, Stefano

    International journal of molecular sciences

    2023  Volume 24, Issue 9

    Abstract: Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital ... ...

    Abstract Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis. Recent data suggest that different interstitial lung diseases with a progressive pulmonary fibrosis phenotype can share similar pathogenetic and biological pathways and could be amenable to antifibrotic therapies. Indeed, historical management strategies in interstitial lung disease have failed to identify potential treatments once progression has occurred despite available drugs. In this systematic review, we summarized data on the efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis as well as ongoing and upcoming clinical trials. We identify two well-designed trials regarding nintedanib demonstrating the efficacy of this drug in slowing disease progression in patients with interstitial lung diseases other than idiopathic pulmonary fibrosis. On the other hand, results on the use of pirfenidone in interstitial lung diseases other than idiopathic pulmonary fibrosis should be interpreted with more caution on the basis of trial limitations. Several randomized control trials are underway to improve the quality of evidence in the interstitial lung disease field.
    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Idiopathic Pulmonary Fibrosis/pathology ; Lung Diseases, Interstitial/drug therapy ; Indoles/therapeutic use ; Pyridones/therapeutic use ; Treatment Outcome
    Chemical Substances nintedanib (G6HRD2P839) ; pirfenidone (D7NLD2JX7U) ; Indoles ; Pyridones
    Language English
    Publishing date 2023-04-25
    Publishing country Switzerland
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24097849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.

    Gramegna, Andrea / Contarini, Martina / Bindo, Francesco / Aliberti, Stefano / Blasi, Francesco

    Current opinion in pharmacology

    2021  Volume 57, Page(s) 81–88

    Abstract: Cystic fibrosis is the most common life-limiting genetic disease in the Caucasian population, with median predicted survival progressively improving up to 50 years, thanks to highly standardized multidisciplinary approach. Patients with p.Phe508del ... ...

    Abstract Cystic fibrosis is the most common life-limiting genetic disease in the Caucasian population, with median predicted survival progressively improving up to 50 years, thanks to highly standardized multidisciplinary approach. Patients with p.Phe508del homozygosity usually have poorer lung function and higher mortality rates per year than other groups. By reason of that, this population has been among the most eligible target of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new class of drugs that can partially restore CFTR function by the correction of CFTR misfolding and trafficking to the cell surface. This narrative review summarizes the current preclinical and clinical evidence of the triple combination of elexacaftor-tezacaftor-ivacaftor, the new benchmark among highly effective CFTR modulators. It provides details on the efficacy and safety that led to drug regulation and approval and discusses future developments in clinical and translational research.
    MeSH term(s) Aminophenols ; Benzodioxoles ; Chloride Channel Agonists/therapeutic use ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Humans ; Indoles ; Mutation ; Pyrazoles ; Pyridines ; Pyrrolidines ; Quinolones
    Chemical Substances Aminophenols ; Benzodioxoles ; Chloride Channel Agonists ; Indoles ; Pyrazoles ; Pyridines ; Pyrrolidines ; Quinolones ; tezacaftor ; Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) ; ivacaftor (1Y740ILL1Z) ; elexacaftor (RRN67GMB0V)
    Language English
    Publishing date 2021-02-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2037057-X
    ISSN 1471-4973 ; 1471-4892
    ISSN (online) 1471-4973
    ISSN 1471-4892
    DOI 10.1016/j.coph.2021.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5608: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review.

    Lombardi, Andrea / Gramegna, Andrea / Ori, Margherita / Azzarà, Cecilia / Blasi, Francesco / Gori, Andrea

    ERJ open research

    2022  Volume 8, Issue 4

    Abstract: Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we ... ...

    Abstract Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the
    Language English
    Publishing date 2022-11-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2827830-6
    ISSN 2312-0541
    ISSN 2312-0541
    DOI 10.1183/23120541.00364-2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.

    Amati, Francesco / Bindo, Francesco / Stainer, Anna / Gramegna, Andrea / Mantero, Marco / Nigro, Mattia / Bussini, Linda / Bartoletti, Michele / Blasi, Francesco / Aliberti, Stefano

    Advances in respiratory medicine

    2023  Volume 91, Issue 3, Page(s) 224–238

    Abstract: A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased ... ...

    Abstract A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant
    MeSH term(s) Humans ; Methicillin-Resistant Staphylococcus aureus ; Community-Acquired Infections/drug therapy ; Pneumonia/drug therapy ; Pneumonia/epidemiology ; Anti-Bacterial Agents/therapeutic use
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2023-05-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2893877-X
    ISSN 2543-6031 ; 2451-4934
    ISSN (online) 2543-6031
    ISSN 2451-4934
    DOI 10.3390/arm91030018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.

    Bongiovanni, Gabriele / Tonutti, Antonio / Stainer, Anna / Nigro, Mattia / Kellogg, Dean L / Nambiar, Anoop / Gramegna, Andrea / Mantero, Marco / Voza, Antonio / Blasi, Francesco / Aliberti, Stefano / Amati, Francesco

    BMJ open respiratory research

    2024  Volume 11, Issue 1

    Abstract: Objectives: Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) ...

    Abstract Objectives: Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) and is associated with high rates of disability, hospitalisation due to cardiac and respiratory illnesses, and mortality. Prior management hinged on treating the underlying lung disease and comorbidities. However, the INCREASE trial of inhaled treprostinil in PH-ILD has demonstrated that PH-ILD can be effectively treated with vasoactive drugs.
    Methods: This comprehensive systematic review examines the evidence for vasoactive drugs in the management of PH-ILD.
    Results: A total of 1442 pubblications were screened, 11 RCTs were considered for quantitative synthesis. Unfortunately, the salient studies are limited by population heterogeneity, short-term follow-up and the selection of outcomes with uncertain clinical significance.
    Conclusions: This systematic review underscores the necessity of establishing a precision medicine-oriented strategy, directed at uncovering and addressing the intricate cellular and molecular mechanisms that underlie the pathophysiology of PH-ILD.
    Prospero registration number: CRD42023457482.
    MeSH term(s) Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Lung Diseases, Interstitial/complications ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/epidemiology ; Comorbidity
    Language English
    Publishing date 2024-03-13
    Publishing country England
    Document type Systematic Review ; Journal Article
    ZDB-ID 2736454-9
    ISSN 2052-4439 ; 2052-4439
    ISSN (online) 2052-4439
    ISSN 2052-4439
    DOI 10.1136/bmjresp-2023-002161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top